CAR T-cell therapy offers a potential new treatment for stiff person syndrome
A CAR T-cell therapy from Kyverna Therapeutics is being developed as a potential treatment for stiff person syndrome, a rare autoimmune disease. If authorized by the U.S. Food and Drug Administration, it would be the first approved therapy for the condition.
CAR T-cell treatments work by modifying a patient’s immune cells so they can recognize and attack specific targets. Kyverna’s experimental approach aims to apply that mechanism to stiff person syndrome, offering an alternative to existing treatments.
Regulatory clearance would be an important next step for the therapy. The article does not provide details about the trial results, safety profile, or timeline for a possible FDA decision, so the treatment’s availability remains uncertain.